X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Concurrent chemoradiotherapy (CCRT) is standard for stage III non-small-cell lung carcinoma (NSCLC) but has limited efficacy and significant side effects.
• Current CCRT regimens struggle to improve survival outcomes and often necessitate dose limitations due to toxicity.

Purpose of the Study:

• To develop an X-ray-responsive polypeptide nanogel (PNG) for on-demand drug delivery.
• To synergistically enhance CCRT efficacy and reduce side effects in NSCLC treatment.

Main Methods:

• Synthesized an X-ray-responsive polypeptide nanogel (mPEG-b-P(LG-co-CELG)) crosslinked with diselenide bonds.
• Loaded the nanogel with doxorubicin (DOX) to create PNG/DOX.
• Evaluated X-ray-triggered DOX release, in vivo pharmacokinetics, and anti-tumor efficacy in A549 lung carcinoma xenografts.

Main Results:

• PNG/DOX demonstrated accelerated doxorubicin release upon X-ray irradiation due to diselenide bond cleavage.
• The nanogel exhibited prolonged circulation and enhanced intratumoral accumulation in vivo.
• Combined PNG/DOX with X-ray irradiation showed superior synergistic anti-tumor efficacy and reduced side effects compared to conventional CCRT.

Conclusions:

• The developed X-ray-responsive nanogel offers a promising strategy for improving CCRT in NSCLC.
• This smart nanogel system facilitates synergistic effects between chemotherapy and radiotherapy.
• The approach holds potential for enhanced clinical application of CCRT with improved safety profiles.